ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,604,250 | -80.7% | 45,000 | -75.0% | 0.02% | -83.8% |
| Q2 2023 | $8,303,400 | +165.4% | 180,000 | +130.7% | 0.15% | +146.7% |
| Q1 2023 | $3,128,762 | +48.4% | 78,024 | +71.5% | 0.06% | +87.5% |
| Q4 2022 | $2,108,015 | -80.2% | 45,500 | -82.3% | 0.03% | -78.2% |
| Q3 2022 | $10,643,000 | -45.2% | 257,100 | -21.0% | 0.15% | -45.1% |
| Q2 2022 | $19,422,000 | +192.7% | 325,534 | +256.2% | 0.27% | +235.0% |
| Q1 2022 | $6,636,000 | -27.3% | 91,400 | +14.0% | 0.08% | -59.2% |
| Q1 2021 | $9,131,000 | +140.7% | 80,201 | +192.7% | 0.20% | +127.9% |
| Q4 2020 | $3,794,000 | -14.5% | 27,400 | -49.3% | 0.09% | -17.3% |
| Q3 2020 | $4,436,000 | -48.3% | 54,000 | -50.8% | 0.10% | -63.6% |
| Q2 2020 | $8,581,000 | +394.9% | 109,700 | +338.8% | 0.29% | +197.9% |
| Q1 2019 | $1,734,000 | – | 25,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |